Bolt Biotherapeutics expands Scientific Advisory Board with appointment of Dr. Priti Hegde
- by Team ABLE - 10 Jan, 2020
Bolt Biotherapeutics, Inc., a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to unleash the power of the immune system to treat cancer, announced the addition ofPriti Hegdeto its scientific advisory board.
Dr. Hegde, who currently serves as chief scientific officer at Foundation Medicine Inc., has spent nearly two decades in the biopharmaceutical industry and has extensive experience with the development, registration and commercialization of therapeutics in cancer immunotherapy.
“Dr Hegde's expertise in cancer immunotherapy drug development will be invaluable as we begin our first clinical study this year and continue to expand our pipeline of innovative myeloid-targeting therapies,” statedDavid Dornan, Bolt's senior vice president of Research. “We have been fortunate that our strong preclinical data and growing team have attracted a world renowned scientific advisory board, and with the addition of Dr. Hegde, we know that their collective wisdom will assist in expediting our ISACs toward those cancer patients unresponsive to checkpoint inhibitors.”
“Bolt's novel ISAC technology and mechanistic understanding of anti-tumor efficacy provides a real scientific advantage to target patients that are unresponsive to immune checkpoint blockade. Having dedicated a significant portion of my career to the field of immunotherapies, this technology registers as one of the most exciting approaches at systemically delivering an agent that has a local immune-stimulating effect at the tumor,” stated Dr. Hegde.
At Foundation Medicine, Dr. Hegde currently oversees clinical product development, cancer genomics and early-stage research, as well as regulatory strategies for the company's comprehensive genomic profiling portfolio.
Prior to joining Foundation Medicine, Dr. Hegde spent 12 years at Genentech, a member of Roche Group, most recently serving as senior director and principal scientist in oncology biomarker development, during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy.
Dr. Hegde was instrumental in the approvals for atezolizumab in both the United States and European Union as well as its forthcoming diagnostic filings. Prior to Genentech, she worked at GlaxoSmithKline. Dr. Hegde completed her post-doctoral fellow at The Institute for Genomic Research and holds a Ph.D. in Biochemical Pharmacology fromSUNY Buffalo, as well as a B. Pharmacy from Mumbai University,India.
Dr. Hegde completed her post-doctoral fellow at The Institute for Genomic Research, holds a Ph.D. in Biochemical Pharmacology from SUNY Buffalo, and a B. Pharmacy from Mumbai University.